1438805-05-0Relevant articles and documents
Two-fold Bioorthogonal Derivatization by Different Formylglycine-Generating Enzymes
Krüger, Tobias,Weiland, Stefanie,Falck, Georg,Gerlach, Marcus,Boschanski, Mareile,Alam, Sarfaraz,Müller, Kristian M.,Dierks, Thomas,Sewald, Norbert
, p. 7245 - 7249 (2018)
Formylglycine-generating enzymes are of increasing interest in the field of bioconjugation chemistry. They catalyze the site-specific oxidation of a cysteine residue to the aldehyde-containing amino acid Cα-formylglycine (FGly). This non-canonical residue can be generated within any desired target protein and can subsequently be used for bioorthogonal conjugation reactions. The prototypic formylglycine-generating enzyme (FGE) and the iron-sulfur protein AtsB display slight variations in their recognition sequences. We designed specific tags in peptides and proteins that were selectively converted by the different enzymes. Combination of the different tag motifs within a single peptide or recombinant protein enabled the independent and consecutive introduction of two formylglycine residues and the generation of heterobifunctionalized protein conjugates.
Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates
Albers, Aaron E.,Garofalo, Albert W.,Drake, Penelope M.,Kudirka, Romas,De Hart, Gregory W.,Barfield, Robyn M.,Baker, Jeanne,Banas, Stefanie,Rabuka, David
, p. 3 - 9 (2014)
In the context of antibody-drug conjugates (ADCs), noncleavable linkers provide a means to deliver cytotoxic small molecules to cell targets while reducing systemic toxicity caused by nontargeted release of the free drug. Additionally, noncleavable linker
ANTI-CD22 ANTIBODY-MAYTANSINE CONJUGATES, COMBINATIONS, AND METHODS OF USE THEREOF
-
, (2019/07/15)
The present disclosure provides methods for treating a cancer or resistant cancer with a combination of an anti-CD22 antibody-maytansine conjugate and one or more anti-cancer agents. The disclosure also encompasses methods for sensitizing a cancer with such combinations. Also provided are pharmaceutical compositions including such combinations.
ANTI-CD22 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF
-
, (2017/08/24)
The present disclosure provides anti-CD22 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
ANTI-HER2 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF
-
, (2015/12/24)
The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
HYDRAZINYL-INDOLE COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE
-
, (2014/05/25)
The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.
